View in EDS HTML Full Text

Callan JMB Agrees With Attune Biotech To Support Its IND Clinical Trials For Treatment Of Post-Acute Sequelae Of SARS-CoV-2 Infection.

Saved in:
Bibliographic Details
Title: Callan JMB Agrees With Attune Biotech To Support Its IND Clinical Trials For Treatment Of Post-Acute Sequelae Of SARS-CoV-2 Infection.
Authors: Benzinga Newsdesk
Source: Benzinga. 03/11/2026.
Abstract: Callan JMB will Provide Independent Manufacturing Oversight and Governance as lodonal™ Undergoes Clinical Trials for Underserved Patient Population SPRING BRANCH, Texas, March 11, 2026 (GLOBE NEWSWIRE) -- Callan JMB Inc. (NASDAQ:CJMB), ("Callan JMB" or the "Company"), an integrative logistics company empowering the healthcare industry and emergency management agencies through fulfillment, storage, monitoring, and cold chain logistics services, today announced that it has agreed with Biostax Corp d/b/a Attune Biotech Inc. ("Attune"), a clinical-stage biopharmaceutical company with a diversified therapeutic pipeline, to support its investigational new drug clinical trials for the treatment of Post-Acute Sequelae of SARS-CoV-2 infection ("PASC"), commonly known as Long COVID. [ABSTRACT FROM PUBLISHER]
Database: Newspaper Source Plus
Full text is not displayed to guests.
Description
Abstract:Callan JMB will Provide Independent Manufacturing Oversight and Governance as lodonal™ Undergoes Clinical Trials for Underserved Patient Population SPRING BRANCH, Texas, March 11, 2026 (GLOBE NEWSWIRE) -- Callan JMB Inc. (NASDAQ:CJMB), ("Callan JMB" or the "Company"), an integrative logistics company empowering the healthcare industry and emergency management agencies through fulfillment, storage, monitoring, and cold chain logistics services, today announced that it has agreed with Biostax Corp d/b/a Attune Biotech Inc. ("Attune"), a clinical-stage biopharmaceutical company with a diversified therapeutic pipeline, to support its investigational new drug clinical trials for the treatment of Post-Acute Sequelae of SARS-CoV-2 infection ("PASC"), commonly known as Long COVID. [ABSTRACT FROM PUBLISHER]